The present invention relates to a composition comprising at least one cocoa polyphenol and soluble dietary fiber for use in the prevention or treatment of a disorder associated with an above-normal number of granulocytes in a tissue.

The present invention relates to a composition comprising at least one cocoa polyphenol and soluble dietary fiber for use in the prevention or treatment of a disorder associated with an above-normal number of granulocytes in a tissue.

The present invention relates to a method of preparing a composition comprising ferulic acid. An aspect of the invention is a composition comprising hydrolysed wheat bran for use in the treatment or prevention of metabolic disease.

The present invention relates to a method of preparing a composition comprising ferulic acid. An aspect of the invention is a composition comprising hydrolysed wheat bran for use in the treatment or prevention of metabolic disease.

Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension. Also, the present invention is based on the finding that the hydrolysate of the flounder surimi and peptides isolated therefrom have radical scavenging effect and a protective effect against oxidative stress and are thus capable of inhibiting ROS production, lipid peroxidation and apoptosis. Accordingly, peptides isolated from fractions of the hydrolysate of the flounder surimi can be used for food compositions for antioxidation.

Disclosed is a lycopene food colorant having a fresh-keeping function. The food colorant is prepared from the following raw materials in parts by weight: 1-3 parts of a lycopene crystal, 5-20 parts of an emulsifier, 0.5-5 parts of an antioxidant, 60-70 parts of glycerol, and 10-20 parts of water. The food colorant is prepared by mixing the raw materials and then emulsifying and grinding same. The granularity of the obtained lycopene colorant is moderate; the tone is suitable for coloring a minced fillet product; the lycopene colorant has high tinting strength, achieves a bright color, and has the effect of triggering myoglobin, so that the minced fillet product has a bright color and appears fresher; the lycopene colorant further has a fresh-keeping function and can kill some food microorganisms, so as to keep food fresh and prolong the shelf life.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agents.

A method for treating a sleep disorder according to an embodiment of the present disclosure includes administering a composition comprising an extract of Hibiscus syriacus as an effective ingredient to a subject in need thereof. Because the Hibiscus syriacus extract of the present invention has an effect of improving sleep time deteriorated by stress, and an effect of reducing the content of corticosterone, which increases due to stress, and increasing the content of serotonin in blood. In addition, the composition has an effect of enhancing in a significant sense the expression of GABAR A α1 in cerebral cortex, which decreases due to stress, in a group administered with Hibiscus syriacus extract. As such, the composition comprising Hibiscus syriacus extract as an effective ingredient as an effective ingredient can be advantageously used as a functional health food composition or a pharmaceutical composition for preventing, ameliorating or treating sleeping disorders.

A method for treating a sleep disorder according to an embodiment of the present disclosure includes administering a composition comprising an extract of Hibiscus syriacus as an effective ingredient to a subject in need thereof. Because the Hibiscus syriacus extract of the present invention has an effect of improving sleep time deteriorated by stress, and an effect of reducing the content of corticosterone, which increases due to stress, and increasing the content of serotonin in blood. In addition, the composition has an effect of enhancing in a significant sense the expression of GABAR A α1 in cerebral cortex, which decreases due to stress, in a group administered with Hibiscus syriacus extract. As such, the composition comprising Hibiscus syriacus extract as an effective ingredient as an effective ingredient can be advantageously used as a functional health food composition or a pharmaceutical composition for preventing, ameliorating or treating sleeping disorders.

Disclosed are nutraceutical formulations, including extracts comprising the hydrophilic and lipophilic fractions of stabilized rice bran. Also disclosed are methods for using said nutraceutical formulations for the management or remediation of conditions related to type II diabetes in humans, including methods for decreasing HbA1c and fasting glucose blood concentrations, and for increasing serum fasting insulin levels.